Each vial contains Piperacillin Sodium and Tazobactam Sodium.

Piperacillin-tazobactum is an injectable antibacterial combination product consisting of the semi synthetic antibiotic piperacillin sodium and the β-lactamase inhibitor tazobactam sodium for intravenous administration.

Piperacillin sodium exerts bactericidal activity by inhibiting cell wall synthesis. Tazobactam sodium has very little intrinsic microbiologic activity due to its very low level binding to penicillin-binding proteins, however, it is a (beta)-lactamase inhibitor of the Richmond-Sykes. Class III penicillinases and cephalosporinases. Tazobactam does not induce chromosomally mediated (beta)-lactamases.

Piperacillin/tazobactam has been shown to be active against most strains of beta lactamase producing micro-organisms both in in-vitro and in clinical infections. It is indicated for the treatment of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible β lactamase producing strains of the microorganisms.

Revotaz 4.5g is available in vial of 30ml.

Each vial of Moclav 1.2g contains: Amoxicillin 1gm and Clavulanic Acid 200mg.

Each vial of Moclav 600mg contains: Amoxicillin 500mg and Clavulanic Acid 100mg.

The Amoxicillin is present as Amoxicillin sodium BP and Clavulanic Acid is present as Clavulanic Potassium USP both in sterile form.

Moclav is a formulation of Amoxicillin, a bactericidal broad spectrum penicillin and Clavulanate potassium, a progressive and irreversible inhibitor of beta-lactamase enzymes. The presence of Clavulanate potassium protects amoxicillin for destruction and subsequent loss of antibacterial activity by the β-lactamase enzymes produced by many gram-negative and gram-positive bacteria. The spectrum of amoxicillin is thus widened to include organisms normally resistant by virtue of their ability to produce β-lactamase.

Moclav will not only eliminate primary pathogens but will also not be inactivated by non-pathogenic β-lactamase producing organisms at the site of infection.

Moclav is indicated for the treatment of common bacterial infections where antibiotic therapy is indicated

Moclav Intravenous is also indicated for prophylax is against infections which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, billary and joint replacement surgery.

Moclav 1.2g is available in vial of 1.2g with 2X10ml water for injection.

Moclav 600mg is available in vial of 600mg with 10ml water for injection.

Each enteric coated tablet contains Pantoprazole Sodium equivalent to Pantoprazole 40mg.

Pantoprazole is a proton pump inhibitor; it inhibits specifically and dose proportionally H+, K+ -ATpase, the enzyme which is responsible for gastric acid secretion in the parietal cells of the stomach.

Pantoprazole is a substituted benzimidazole which accumulates in the acidic compartment of the parietal cells after absorption. In the parietal cell it is protonated and chemically rearranged to the active inhibitor, a cyclic sulphenamide, which binds to the H+, K+ -ATpase thus inhibiting the proton pump and causing suppression of stimulated and basal gastric acid secretion after oral Pantoprazole dosing. Because Pantoprazole acts distal to the receptor level, it can influence gastric acid secretion irrespective of the nature of the stimulus.

Pantoprazole exerts its full effect in a strongly acidic environment (Ph<3) and remains mostly inactive at higher pH values which explains its selectively for the acid secreting parietal cells of the stomach. Therefore, the complete pharmacological and therapeutic effect for Pantoprazole can only be achieved in the acid-secreting parietal cells. By means of a feedback mechanism this effect is diminished at the same rate as acid secretion is inhibited.

Pantoprazole is unstable in acid and is administered orally in the form of an enteric-coated tablet. Absorption takes place in the small intestine. On average, the maximum serum/plasma concentrations are approximately 2 to 3 microorganisms/mL about 2 ½ hours after administration of 40mg Pantoprazole daily , as a single or multiple dose in healthy volunteers. The absolute bioavailability of Pantoprazole from single and multiple oral doses of Pantoprazole is approximately 77%.

The plasma kinetics for Pantoprazole after both oral and intravenous administration is linear over the dose range 10 - 80mg.

Pantoprazole is almost exclusively metabolised in the liver. The main metabolite is desmethylpantoprazole which is conjugated with Sulphate.

Renal elimination represents the most important route of excretion (approximately 80%) for the metabolites of Pantoprazole. The balance is excreted with the faeces. The half-life of the main metabolite is approximately 1 ½ hours which is slightly longer than that of Pantoprazole.

Pantoprazole 40 is indicated for the short-term treatment duodenal ulcer, gastric ulcer and reflux esophagitis. If the duodenal ulcer has been demonstrated to be associated with Helicobacter pylori infection, Pantoprazole 40 used in combination with appropriate antibiotics may be useful.

Pantoprazole 40 is available in blister strips of 10 tablets.

Moclav 375 tablets: Each film-coated tablet contains 250mg Amoxicillin and 125mg Clavulanic Acid.

Moclav 625 tablets: Each film-coated tablet contains 500mg Amoxicillin and 125mg Clavulanic Acid. Moclav 1000 tablets: Each film-coated tablet contains 875mg Amoxicillin and 125mg Clavulanic Acid.

Moclav Tablet is a beta-lactam antibiotic that inhibits the cell wall synthesis of bacteria and hence acts as a bactericidal drug.

Combining Clavulanic acid with their amoxicillin causes no appreciable alteration of the pharmacokinetics of either drug compared with their separate administration. After oral administration, both components achieve maximum plasma concentration in about 1 hour and these concentrations show a direct relationship to the dose administered. The absolute bioavailability of Clavulanic acid is about 60%. Absorption is unaffected by concomitant administration of food, milk etc.

Clavulanic acid has a volume of distribution of about 25% of body weight and is about 22% protein bound in vitro. Both Clavulanic Acid and Amoxicillin possess a mean elimination of half-life of about 1 hour and a mean total clearance of about 25L/h in healthy subjects. The main route of elimination is via the urine.

Moclav tablets are indicated for the treatment of tonsillitis, sinusitis, otits media, acute and chronic bronchitis, lobar and bronchopneumonia, cystitis, urethritis, pyelonephritis, boils, abscesses, cellulites, wound infections and dentoslveolar abscess.

Moclav 375 tablets are available in strips of 7 or 10 tablets.

Moclav 625 tablets are available in strips of 7 or 10 tablets.

Moclav 1000 tablets are available in strips of 10 tablets.